| Exec date | Filing date | Company | Role | Signal | Confidence | Shares | % of shares | Under plan? | Amount (USD) |
|---|---|---|---|---|---|---|---|---|---|
| Dec 4, 2025 | Dec 8, 2025 | Vaxart, Inc. | President | Sell | 86.3 | +97,198 | 5.43% | ✗ | $20K |
| May 19, 2025 | May 19, 2025 | Vaxart, Inc. | President | Buy | 91.3 | +100,000 | 100.00% | ✗ | $49K |
| Mar 18, 2025 | Mar 20, 2025 | Vaxart, Inc. | President | Sell | 46.3 | -22,362 | -8.94% | ✗ | $12.8K |
| Jul 22, 2019 | Jul 24, 2019 | PUMA BIOTECHNOLOGY, INC. | Chief Commercial Officer | Sell | 32.5 | -1,852 | -8.65% | ✓ | $18.6K |
| Jan 22, 2019 | Jan 24, 2019 | PUMA BIOTECHNOLOGY, INC. | Chief Commercial Officer | Sell | 28.8 | -2,114 | -8.99% | ✓ | $52.7K |
| Jul 20, 2018 | Jul 24, 2018 | PUMA BIOTECHNOLOGY, INC. | Chief Commercial Officer | Sell | 32.5 | -1,839 | -7.25% | ✓ | $95.4K |
| Jan 22, 2018 | Jan 24, 2018 | PUMA BIOTECHNOLOGY, INC. | Chief Commercial Officer | Sell | 32.5 | -1,858 | -6.83% | ✓ | $172.5K |
| Jul 20, 2017 | Jul 24, 2017 | PUMA BIOTECHNOLOGY, INC. | Chief Commercial Officer | Sell | 32.5 | -1,990 | -6.81% | ✓ | $188.9K |
| Jan 20, 2017 | Jan 24, 2017 | PUMA BIOTECHNOLOGY, INC. | Chief Commercial Officer | Sell | 32.5 | -2,290 | -7.27% | ✓ | $76.1K |
| Nov 2, 2015 | Nov 3, 2015 | CORCEPT THERAPEUTICS INC | VP Commercial Operations | Sell | 22.5 | -12,500 | -100.00% | ✗ | $50K |
| Oct 13, 2015 | Oct 15, 2015 | CORCEPT THERAPEUTICS INC | VP Commercial Operations | Sell | 22.5 | -53,033 | -100.00% | ✗ | $202.6K |
| Oct 7, 2015 | Oct 9, 2015 | CORCEPT THERAPEUTICS INC | VP Commercial Operations | Sell | 26.3 | -5,300 | -9.09% | ✗ | $21.2K |
| Oct 6, 2015 | Oct 7, 2015 | CORCEPT THERAPEUTICS INC | VP Commercial Operations | Sell | 22.5 | -50,000 | -46.15% | ✗ | $188K |